Pre-earnings brief
Reports
Wed, Oct 21, 2026
Est. EPS
$2.65
Est. revenue
$2.0B
Implied move
±12.9%
EPS beat rate
75%
ICON Public Limited Company (ICLR) operates in the health care sector, specifically in life sciences tools and services. The company plays a crucial role in supporting pharmaceutical and biotechnology companies with clinical development and commercialization services, which are vital for bringing new drugs to market.
Last quarter
In Q2 2026, ICON reported an EPS of $2.56, exceeding expectations by 13.42%. However, revenue details were not disclosed, leading to a slight decline in stock price the following day.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+5.31%
Avg 1-day reaction
+1.22%
Analysts are generally optimistic about ICON's upcoming earnings, expecting solid performance based on previous results. The consensus EPS estimate suggests confidence in continued growth.
Bull case
If ICON beats EPS estimates and shows strong revenue growth, it could signal robust demand for its services, leading to a positive market reaction.
Bear case
Conversely, if ICON fails to meet EPS expectations or provides weak guidance, it could raise concerns about its growth trajectory, resulting in a negative impact on the stock.
Key metrics to watch
EPS
$2.65Earnings per share is a key indicator of the company's profitability and growth potential.
Revenue
$2.0BRevenue figures provide insight into the company's overall performance and market demand for its services.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $2.65?
A beat on EPS would reinforce confidence in ICON's growth and profitability, potentially leading to a positive stock reaction.
Q2
What insights will management provide regarding revenue growth?
Understanding revenue trends is crucial for assessing the company's market position and future prospects.
—
Est. EPS
$0.24
Est. Rev
$5.7B
Impl. Move
±13.0%
Why consensus could be wrong
The Street may underestimate ICON's ability to exceed EPS expectations due to strong demand in the life sciences sector, which could drive better-than-expected results.
Supporting evidence
ICON has consistently beaten EPS estimates in recent quarters, suggesting a trend of strong performance.
The options market is pricing a significant move, indicating that traders expect volatility that may not align with consensus expectations.
Key risk
If revenue growth significantly outpaces expectations, it could challenge the current consensus view.
Pre-commit to what would confirm each case.
This quarter's performance will be closely scrutinized as it follows a strong EPS surprise last quarter, and any deviation could significantly impact investor sentiment.
Bull confirmed if
An EPS of $2.70 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $2.56 would raise concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±12.86%
Historical Avg
±1.8%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±12.9% while ICLR has averaged ±1.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
41.8%
Smart-money positioning from the most recent 13F filings.
Institutional
108.21%
of float
Insider
0.44%
of float
Holders
619
institutions
Top Holders· as of Jun 2026
Artisan Partners Limited Partnership
8,636,406 sh · $1.4B
11.31%
4.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ICON beats expectations, history suggests a positive reaction, averaging a +1.12% move on such outcomes.
In line / cautious
If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess growth prospects.
Miss
If ICON misses EPS estimates, the stock could drop, as history indicates an average decline of -0.96% following such misses.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Wellington Management Group, LLP
5,320,054 sh · $872.9M
6.97%
-10.0%
FMR, LLC
5,271,321 sh · $864.9M
6.90%
26.3%
Invesco Ltd.
5,264,236 sh · $863.8M
6.89%
35.7%
Harris Associates L.P.
4,468,146 sh · $733.1M
5.85%
2.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 14, 2026 · disclosed Sep 1, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.